The following video is part of our "Motley Fool Conversations" series, in which, Eric Bleeker, senior technology editor, and James Early, advisor, discuss topics around the investing world.
In today's edition, James suggests that dividend-focused investors look toward Johnson & Johnson. While there's been a high degree of pessimism surrounding the company as it's faced product recalls and other product missteps, James says the company is essentially a "mutual fund for the health-care industry" and has been unfairly beaten down.
If you're interested in Johnson & Johnson on your quest for great high-yielders, The Motley Fool has compiled a special free report outlining our 11 favorite, dependable dividend-paying stocks. It's called "Secure Your Future With 11 Rock-Solid Dividend Stocks." You can access your complimentary copy today at no cost. Just click here to discover the winners we've picked.
At the time thisarticle was published Eric Bleeker owns no shares of the companies listed above. James Early and The Motley Fool own shares of Johnson & Johnson.Motley Fool newsletter serviceshave recommended buying shares of Johnson & Johnson and Pfizer and creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter servicesfree for 30 days. We Fools don't all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.
Copyright © 1995 - 2011 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.